Afelimomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Afelimomab ?
Monoclonal antibody
Type F(ab')2 fragment
Source Mouse
Target TNFα
Clinical data
Legal status
?
Identifiers
CAS number 156227-98-4 N
ATC code L04AB03
KEGG D07436 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]

References[edit]

  1. ^ Rondon, E.; Venkataraman, R. (2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.  edit
  2. ^ Panacek, E. A.; Marshall, J. C.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D.; Miller, M.; Barchuk, W. T.; Fischkoff, S.; Kaul, M.; Teoh, L.; Van Meter, L.; Daum, L.; Lemeshow, S.; Hicklin, G.; Doig, C.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine 32 (11): 2173–2182. PMID 15640628.  edit